$IOVA News

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note

IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen

Iovance (IOVA) Surges 9.4% on Regulatory Nod

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds

H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA)

Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?

Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001

Iovance Biotherapeutics: Progress With Caveats

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption

A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For Amtagvi

Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?

Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15%

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

Iovance Biotherapeutics Says Therapeutic Goods Administration Of Australia Grants Approval With Conditions Of Amtagvi, Tumor-Derived Autologous T Cell Immunotherapy, For Previously Treated Advanced Melanoma

Does FDA Clearance for IOV-5001 TIL-IL12 Trial Change The Bull Case For Iovance Biotherapeutics (IOVA)?

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001